Award
Sterne Kessler Wins PTAB Firm of the Year and Design Patent Firm of the Year
Eldora Ellison Named PTAB Practitioner of the Year
2026 Managing IP Americas Awards
Read More
Featured Experience
PTAB Trials: IPRs, PGRs, DERs
Sterne Kessler’s PTAB Trials team is deeply experienced in all proceedings at the PTAB, including inter partes reviews (IPRs), post-grant reviews (PGRs), and derivation proceedings (DERs). We emerged as a leader at the inception of the PTAB, and continue to be a dominant force in the industry today. We are among the top 10 most active firms at the PTAB, representing petitioners and patent owners across all technologies, including biotechnology, electronics, consumer products, automotive, and many others.
Artificial Intelligence
In the rapidly evolving world of artificial intelligence (AI), safeguarding your intellectual property (IP) is critical. As a market and thought leader in the technology sector, Sterne Kessler helps clients develop comprehensive IP solutions that protect innovation, foster growth, and maximize value. Whether you are an emerging startup company or a well-established technology pioneer, we are committed to helping you harness the full potential of AI technology.
Pharmaceutical Patent Litigation
At Sterne Kessler, we know what it takes to win across any venue in pharmaceutical IP litigation. Our award-winning team has a deep bench of experienced litigators representing biosimilars as well as generic and specialty brand pharmaceutical companies in high-profile patent litigation, including blockbuster Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters.
ITC Litigation
With one of the nation’s top ITC practices, Sterne Kessler offers unrivaled experience, comprehensive litigation strategy, and the legal and technical know-how to achieve the best possible results. In the last five years, Sterne Kessler has handled more cases at the ITC than 90% of firms appearing before the Commission.
Design Patents
For nearly four decades, Sterne Kessler has been at the forefront of design patents, consistently delivering successful outcomes for clients in securing and defending their design rights. We develop effective, comprehensive IP programs to protect some of the most iconic product designs in the world and to eliminate knock-offs in the marketplace.
Featured News
More News & Insights
Sixteen Sterne Kessler Lawyers Recognized in WIPR Leaders 2026
Washington, D.C. (May 5, 2026) – Sterne, Kessler, Goldstein & Fox is proud to announce that sixteen of our directors earned recognition in the 2026 edition of World…
Sterne Kessler Named Life Sciences Patent Strategy Firm of the Year at LSPN Awards USA 2026
Washington, D.C. (May 1, 2026) – Sterne, Kessler, Goldstein & Fox received the Life Sciences Patent Strategy Firm of the Year award at the 2026 LSPN Awards USA…
Short Stack, Tall Problem: Branding Guides and Functionality at the TTAB
In its first precedential decision of 2026, the Trademark Trial and Appeal Board served up a cautionary tale in In re Misty Everson and Christine Maynard, Serial No.…
Sterne Kessler Obtains Settlement for Dexcel Pharma
Washington, D.C. (April 29, 2026) – Sterne, Kessler, Goldstein & Fox represented client Dexcel Pharma in connection with a settlement agreement resolving patent litigation brought by Pfizer Inc.…
What To Watch as Justices Take on “Skinny Label” Case
William Milliken, director and co-chair of Sterne Kessler’s appellate practice, spoke to Law360 on the possible impacts from the upcoming U.S. Supreme Court case Hikma Pharmaceuticals USA Inc.…
Protecting Innovation for Psychedelic Therapies Fast-Tracked Under New Executive Order
On April 18, 2026, President Trump signed an Executive Order to accelerate FDA approval of certain psychedelic therapies for mental illness. Keep reading to find out what the…
Your innovations are worth the best protection
Expertise
Sterne Kessler is a full-service IP firm that delivers innovative solutions tailored to your business and industry.